Clinical trials: Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes.
- Trial name
- NCT05387278
- Testing
- EV-Pure™ and WJ-Pure™
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vitti Labs, LLC
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).
- Trial name
- NCT04366830
- Testing
- Remestemcel-L
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Covid19, ARDS
Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome
Non-invasive ventilation can allow to avoid intubation and improve outcomes in moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS).
- Trial name
- COVID-NIV (NCT04667923)
- Testing
- Respiratory monitoring, Respiratory muscles ultrasound, Electro impedance tomography
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University